Objective: To evaluate the treabnent outcomes In non-small cell lung cancer stage IllB-IV patients treated with Docetaxel and Carboplatin combination regimen. Patients and Methods: Sixty-five patients with non-small cell lung cancer stage IllB-IV which had been treated with Docetacel and Carboplatin combination regimen between 2009 and 2014 at National Cancer Hospital and Hanoi Medical University Hospital, were retrospectively investigated. The primary endpoint was overall surviall (OS) and disease free survival (DFS). Result: Median OS was 11 + or - 0,9 months (0 95 percent). OS 1 year was 34,6 percent, OS 2 year was 4,2 percent. DFS was 3,2 + or - 0,6 months (0 95 percent). OS 1 year at under 60 years of age (32,1 percent) was higher than patients aged older than 60 years (9,4 percent), p=0,008. OS 1year of group grade Tl/2, T3/4 was 31,8 percent and 7,8 percent of patents, respectively (p=0,0354). OS 1 year of group patients which had been treated with 6 cours or more was higher than group treated under 6 cours ( 21,7 percent vs 9,2 percent, respectively) p = 0,0002. OS of group patients response to treatment and no response to treatment was 29,9 percent and 3,1 percent, respectively p 0,001. A group of patients aged 60 years or younger and response to treatment had DFS 1 year higher than group of patients older than 60 years and no response to treatment (11,4 percent and 12,4 percent vs 3,4 percent and 4 percent, respectively) p
Lọc theo danh mục
Lượt truy cập :
30,101,000
Xem toàn văn